Labcorp provides genotypic testing and is the only company to provide HIV phenotypic testing, as well as combination genotypic/phenotypic testing for determining patient ARV susceptibility.
Genotype testing provides a prediction of drug susceptibility based on a patient’s viral mutational profile.
Phenotype testing provides an assessment of drug susceptibility based direct observation of viral inhibition in the presence of drugs.
Combination genotypic/phenotypic testing provides the most complete view of drug susceptibility, combining the susceptibility calls of phenotyping with the mutational information gained derived from genotyping.
Tropism testing assesses the mechanisms by which HIV gains access to CD4 cells when a CCR5 antagonist is being considered for treatment.
Suppression management is available for patients who have established viral suppression and who may have reason for regimen modification. Genotypic testing interrogating the viral archive along with tropism testing of the DNA compartment provide data to support treatment changes without treatment interruption.
